Deciphering a Specific Signature of the Immunosenescence Induced in COVID-19+ Patients Versus Rheumatoid Arthritis Patients

Inclusion Criteria for Active RA Patients: * Patients with rheumatoid arthritis (RA) meeting the 2010 ACR/EULAR diagnostic criteria * Patients in inflammatory flare of RA (DAS28 \> 3.2) * Patients who have been off biological disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic antirheumatic drugs (tsDMARDs) for RA for at least 2 weeks (except for rituximab, where a delay of at least 12 months is required) * Conventional synthetic DMARDs (Methotrexate, Hydroxychloroquine, Leflunomide, Sulfasalazine) are allowed * Beneficiary of a social security system * Informed consent Inclusion Criteria for Healthy Controls: * Absence of chronic diseases and current infection * Beneficiary of a social security system * Informed consent Inclusion Criteria for COVID-19+ Patients: * Patients with ongoing SARS-Cov-2 infection (PCR+) * Patients hospitalized at D7-D14 of symptoms onset * Patients with two or more SARS-Cov-2 symptoms (including fever, cough, dyspnea, sore throat, chest pain, anosmia, diarrhea) * Membership in or beneficiary of a social security scheme * Collection of free and informed consent Exclusion Criteria for All Groups: * Subjects under 18 years of age * HIV positive patients * Diabetic patients * Morbidly obese patients (BMI \> 40kg/m2) * Use of senolytic drugs in the week prior to inclusion (azithromycin, metformin, cyclosporine, JAK inhibitors) * Use of steroids in doses greater than 10 mg/day in the week prior to inclusion * Subjects unable to give consent * Pregnant, breastfeeding, or non-menopausal women not taking effective contraception * Vulnerable subjects protected by law * Subjects under guardianship or curatorship